Celltrion expects 90 percent surge in Australian sales of Remicade clone
Celltrion expects a nearly 90-percent on-year surge in its Remicade copycat drug sales in Australia in 2023 to 15 billion won ($11.4 million), the biopharmaceutical company said Thursday.
